Contact Us Site Map

Our Board of Directors

Malcolm L. Gefter, Ph.D.
Malcolm L. Gefter, Ph.D., founded PRAECIS and has served as a director since July 1993, as Chairman of the Board since February 1994 and as our Chief Scientific Officer since January 2005. Dr. Gefter served as our Chief Executive Officer from July 1996 until January 2005. From July 1998 to May 2002, Dr. Gefter was also our President and from July 1993 to July 1998, he was our Treasurer. Dr. Gefter has been a professor of biology at the Massachusetts Institute of Technology and is now professor emeritus. He has authored more than 200 original scientific papers. Dr. Gefter was a founder of ImmuLogic Pharmaceutical Corporation, and from 1987 to March 1997, served as Chairman of the Board of Directors of ImmuLogic. Dr. Gefter received his B.S. in Chemistry from the University of Maryland and his Ph.D. in Molecular Biology from Albert Einstein College of Medicine.

Kevin F. McLaughlin
Mr. McLaughlin was appointed as a Director and as Chief Executive Officer in January 2005 and has been serving as President since September 2004. Mr. McLaughlin served as Chief Operating Officer from September 2004 until January 2005. Prior to this, Mr. McLaughlin served the Company as Chief Financial Officer since September 1996 and Secretary since January 1997.

Prior to joining PRAECIS, Mr. McLaughlin was vice president and chief financial officer of Advanced Techcom, Inc., a privately held communications company. Between 1980 to 1996, he held senior level financial positions at Computervision Corporation and its predecessor Prime Computer, Inc., including vice president, treasurer and director of corporate planning, where he was involved with financial, accounting and investor relations management, as well as public and private financing.

Mr. McLaughlin received his B.S. in accounting from Northeastern University and his MBA from Babson College.

G. Leonard Baker, Jr.
G. Leonard Baker, Jr. has served as a member of our Board of Directors since March 1994. Since 1974, Mr. Baker has been a Managing Director or General Partner of Sutter Hill Ventures, a venture capital firm. Mr. Baker also serves as a director of Therma-Wave, Inc., Corcept Therapeutics Inc., and a number of private companies.

Garen G. Bohlin
Garen G. Bohlin has served as a member of our Board of Directors since July 2003. Mr. Bohlin is the President and Chief Operating Officer of Sirtris Pharmaceuticals, Inc. Prior to joining Sirtris, Mr. Bohlin served as President and Chief Executive Officer of Syntonix Pharmaceuticals, Inc., from September 1998 through July 2005. Prior to that time, Mr. Bohlin spent 14 years at Genetics Institute, Inc. (GI). In his last position at GI, he served as Executive Vice President with responsibility for essentially all of the non-scientific areas of GI that comprised approximately half of the company's then 1,600 employees. Prior to GI, Mr. Bohlin spent 13 years at Arthur Andersen where, as partner, he oversaw all client activities for a broad range of Fortune 500 businesses, as well as smaller publicly and privately owned companies. He serves as a director of Syntonix Pharmaceuticals, Inc. and Acusphere, Inc., and was past chair and a director of the Massachusetts Biotechnology Council.

Henry F. McCance
Henry F. McCance has served as a member of our Board of Directors since December 1993. Mr. McCance has been employed at Greylock Management Corporation, a private venture capital group, since 1969, where he has been President since 1990 and Chairman of the Board since 1997. Mr. McCance is a general partner of several venture capital funds affiliated with Greylock. He also serves as a director of Cabot Corporation.

Leonard E. Post, Ph.D.
Leonard E. Post, Ph.D. has served as a member of our Board of Directors since September 2003. Dr. Post is currently a privately employed scientific consultant. From July 2000 to January 2006, Dr. Post was the Senior Vice President of Research and Development at Onyx Pharmaceuticals, Inc. Prior to joining Onyx Pharmaceuticals in 2000, Dr. Post spent nine years at the Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company, where he held various management positions, including Vice President, Discovery. From 1981 to 1991, Dr. Post spent ten years at The Upjohn Company in various scientific and management positions. From 1993 to June 2000, Dr. Post also served as an adjunct professor in the Department of Microbiology and Immunology at the University of Michigan and from 1990 to 1994, he was a member of the NIH Recombinant DNA Advisory Committee.

David B. Sharrock
David B. Sharrock has served as a member of our Board of Directors since February 1994. Since 1994, Mr. Sharrock has been a privately employed business consultant. From 1990 to 1994, Mr. Sharrock was Executive Vice President and Chief Operating Officer of Marion Merrell Dow Inc., a global pharmaceutical company, and from 1988 to 1989, he was President and Chief Operating Officer of Merrell Dow Pharmaceuticals, Inc. Mr. Sharrock also serves as a director of Cincinnati Bell, Inc., Indevus Pharmaceuticals, Inc., Incara Pharmaceuticals Corporation and MGI Pharma, Inc.

Patrick J. Zenner
Patrick J. Zenner has served as a member of our Board of Directors since July 2001. Mr. Zenner served as the interim Chief Executive Officer and Chairman of the Board of Curagen Corporation from May 2005 until March 2006. In January 2001, Mr. Zenner retired from Hoffmann La Roche Inc., North America, the prescription drug unit of the Roche Group, a leading research based health care enterprise, where he served as President and Chief Executive Officer since 1993, and was a member of the global Pharmaceutical Executive Committee. Mr. Zenner joined Hoffmann La Roche Inc. in 1969 and held a number of executive positions both internationally and domestically during his tenure. Mr. Zenner also serves as a director of Dendrite International, Inc., Geron Corporation, Curagen Corporation, ArQule, Inc., West Pharmaceutical Services, Inc., First Horizon Pharmaceutical Corporation, XOMA, Ltd., EXACT Sciences Corporation and other private companies.